SKYE BIOSCIENCE INC Stock Prediction
AI-powered sentiment analysis and prediction trends for SKYE, updated each market day.
SKYE AI Sentiment
AI predicts SKYE BIOSCIENCE INC stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About SKYE BIOSCIENCE INC
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Sector
Exchange
Market Cap
$24,226,306
Cap Tier
Employees
12
Headquarters
SAN DIEGO, CA
Listed Since
Feb. 24, 2014
Website
SKYE Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SKYE Volatility
SKYE BIOSCIENCE INC has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
